1.3. Diarrhoea
|
|
This High-Cost Drug has been approved for the following indications: - treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| For more information and NICE Guidance Click Here | Infliximab for treating moderately to severely active ulcerative colitis NICE TA329 ICB commissioned - approval via Blueteq |
Infliximab
| Pack |
|---|
| 10 capsule |
| 12 capsule |
| 18 capsule |
| 250 capsule |
| 30 capsule |
| 6 capsule |
| 8 capsule |
Initiated and monitored under the guidance of a gastroenterologist and oncologist for the treatment of severe Immune Checkpoint Inhibitor related diarrhoea or colitis grade 3 or 4, in line with the St Luke’s Cancer Alliance
- First Line Choice
- On Formulary
- Specialist Initiation Only
- Hospital Only
- KMPT Initiation Only